Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors

European Journal of Immunology

Volumn 41, Issue 8, 2011, Pages 2379-2389

  Konya, Viktoria ^a   Philipose, Sonia ^a   Bálint, Zoltán ^a   Olschewski, Andrea ^a   Marsche, Gunther ^a   Sturm, Eva M ^a   Schicho, Rudolf ^a   Peskar, Bernhard A ^a   Schuligoi, Rufina ^a   Heinemann, Akos ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adhesion; Endothelium; Eosinophils; Migration; Prostaglandins

Indexed keywords

BETA2 INTEGRIN; EOTAXIN; FIBRONECTIN; GELSOLIN; L SELECTIN; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; EOSINOPHIL; HOMEOSTASIS; HUMAN; HUMAN CELL; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

ANTIGENS, CD18; CELL ADHESION; CELL COMMUNICATION; CELL LINE; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL11; CYCLOPENTANES; DINOPROSTONE; ENDOTHELIAL CELLS; EOSINOPHILS; FIBRONECTINS; FLOW CYTOMETRY; GELSOLIN; HUMANS; L-SELECTIN; MICROSCOPY, CONFOCAL; NAPHTHALENES; PHENYLBUTYRATES; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; THIOGLYCOLATES; THROMBIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960732797     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141460     Document Type: Article

References (62)

1. Jose, P. J., Griffiths-Johnson, D. A., Collins, P. D., Walsh, D. T., Moqbel, R., Totty, N. F., Truong, O. et al., Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med. 1994. 179: 881-887.
2. Ebisawa, M., Yamada, T., Bickel, C., Klunk, D. and Schleimer, R. P., Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J. Immunol. 1994. 153: 2153-2160.
3. Garcia-Zepeda, E. A., Combadiere, C., Rothenberg, M. E., Sarafi, M. N., Lavigne, F., Hamid, Q., Murphy, P. M. et al., Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J. Immunol. 1996. 157: 5613-5626.
4. Uden, A. M., Palmblad, J., Lindgren, J. A. and Malmsten, C., Effects of novel lipoxygenase products on migration of eosinophils and neutrophils in vitro. Int. Arch. Allergy Appl. Immunol. 1983. 72: 91-93.
5. Monneret, G., Gravel, S., Diamond, M., Rokach, J. and Powell, W. S., Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001. 98: 1942-1948.
6. Jacobsen, E. A., Taranova, A. G., Lee, N. A. and Lee, J. J., Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J. Allergy Clin. Immunol. 2007. 119: 1313-1320.
7. Aceves, S. S. and Broide, D. H., Airway fibrosis and angiogenesis due to eosinophil trafficking in chronic asthma. Curr. Mol. Med. 2008. 8: 350-358.
8. Navarro, S., Aleu, J., Jimenez, M., Boix, E., Cuchillo, C. M. and Nogues, M. V., The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell. Mol. Life Sci. 2008. 65: 324-337.
9. Foster, P. S., Rosenberg, H. F., Asquith, K. L. and Kumar, R. K., Targeting eosinophils in asthma. Curr. Mol. Med. 2008. 8: 585-590.
10. Schuligoi, R., Grill, M., Heinemann, A., Peskar, B. A. and Amann, R., Sequential induction of prostaglandin E and D synthases in inflammation. Biochem. Biophys. Res. Commun. 2005. 335: 684-689.
11. Park, G. Y. and Christman, J. W., Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006. 290: L797-L805.
12. Schuligoi, R., Sturm, E., Luschnig, P., Konya, V., Philipose, S., Sedej, M., Waldhoer, M. et al., CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 2010. 85: 372-382.
13. Vancheri, C., Mastruzzo, C., Sortino, M. A. and Crimi, N., The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 2004. 25: 40-46.
14. Aggarwal, S., Moodley, Y. P., Thompson, P. J. and Misso, N. L., Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation. Clin. Exp. Allergy 2010. 40: 85-93.
15. Martin, J. G., Suzuki, M., Maghni, K., Pantano, R., Ramos-Barbon, D., Ihaku, D., Nantel, F. et al., The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat. J. Immunol. 2002. 169: 3963-3969.
16. Alfranca, A., Iniguez, M. A., Fresno, M. and Redondo, J. M., Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc. Res. 2006. 70: 446-456.
17. Norel, X., Prostanoid receptors in the human vascular wall. Sci. World J. 2007. 7: 1359-1374.
18. Sturm, E. M., Schratl, P., Schuligoi, R., Konya, V., Sturm, G. J., Lippe, I. T., Peskar, B. A. et al., Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J. Immunol. 2008. 181: 7273-7283.
19. Gaspar-Elsas, M. I., Queto, T., Vasconcelos, Z., Jones, C. P., Lannes-Vieira, J. and Xavier-Elsas, P., Evidence for a regulatory role of alpha 4-integrins in the maturation of eosinophils generated from the bone marrow in the presence of dexamethasone. Clin. Exp. Allergy 2009. 39: 1187-1198.
20. Nourshargh, S., Hordijk, P. L. and Sixt, M., Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat. Rev. Mol. Cell. Biol. 2010. 11: 366-378.
21. Aota, S. and Yamada, K. M., Fibronectin and cell adhesion: specificity of integrin-ligand interaction. Adv. Enzymol. Relat. Areas Mol. Biol. 1995. 70: 1-21.
22. Mohri, H., Fibronectin and integrins interactions. J. Investig. Med. 1996. 44: 429-441.
23. Lishko, V. K., Yakubenko, V. P. and Ugarova, T. P., The interplay between integrins alphaMbeta2 and alpha5beta1 during cell migration to fibronectin. Exp. Cell. Res. 2003. 283: 116-126.
24. Kumar, N. and Khurana, S., Identification of a functional switch for actin severing by cytoskeletal proteins. J. Biol. Chem. 2004. 279: 24915-24918.
25. Barthel, S. R., Johansson, M. W., McNamee, D. M. and Mosher, D. F., Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J. Leukoc. Biol. 2008. 83: 1-12.
26. Saltel, F., Mortier, E., Hytonen, V. P., Jacquier, M. C., Zimmermann, P., Vogel, V., Liu, W. et al., New PI(4, 5)P2- and membrane proximal integrin-binding motifs in the talin head control beta3-integrin clustering. J. Cell. Biol. 2009. 187: 715-731.
27. Lukacs, N. W., Strieter, R. M., Chensue, S. W., Widmer, M. and Kunkel, S. L., TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J. Immunol. 1995. 154: 5411-5417.
28. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am. J. Respir. Crit. Care. Med. 2000. 162: 2341-2351.
29. Moore, W. C. and Peters, S. P., Severe asthma: an overview. J. Allergy Clin. Immunol. 2006. 117: 487-494; quiz 495.
30. Chanez, P., Wenzel, S. E., Anderson, G. P., Anto, J. M., Bel, E. H., Boulet, L. P., Brightling, C. E. et al., Severe asthma in adults: what are the important questions? J. Allergy Clin. Immunol. 2007. 119: 1337-1348.
31. Howarth, P. H., Babu, K. S., Arshad, H. S., Lau, L., Buckley, M., McConnell, W., Beckett, P. et al., Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005. 60: 1012-1018.
32. Berry, M. A., Hargadon, B., Shelley, M., Parker, D., Shaw, D. E., Green, R. H., Bradding, P. et al., Evidence of a role of tumor necrosis factor alpha in refractory asthma. N. Engl. J. Med. 2006. 354: 697-708.
33. Erin, E. M., Leaker, B. R., Nicholson, G. C., Tan, A. J., Green, L. M., Neighbour, H., Zacharasiewicz, A. S. et al., The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am. J. Respir. Crit. Care. Med. 2006. 174: 753-762.
34. Morjaria, J. B., Chauhan, A. J., Babu, K. S., Polosa, R., Davies, D. E. and Holgate, S. T., The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008. 63: 584-591.
35. Rennard, S. I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J., Mahler, D. et al., The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 2007. 175: 926-934.
36. Terada, M., Kelly, E. A. and Jarjour, N. N., Increased thrombin activity after allergen challenge: a potential link to airway remodeling? Am. J. Respir. Crit. Care. Med. 2004. 169: 373-377.
37. Kanazawa, H. and Yoshikawa, T., Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways. Chest 2007. 132: 1169-1174.
38. Schouten, M., Van de Pol, M. A., Levi, M., Van der Poll, T. and Van der Zee, J. S., Early activation of coagulation after allergen challenge in patients with allergic asthma. J. Thromb. Haemost. 2009. 7: 1592-1594.
39. Feistritzer, C., Mosheimer, B. A., Kaneider, N. C., Riewald, M., Patsch, J. R. and Wiedermann, C. J., Thrombin affects eosinophil migration via protease-activated receptor-1. Int. Arch. Allergy Immunol. 2004. 135: 12-16.
40. Luschnig-Schratl, P., Sturm, E. M., Konya, V., Philipose, S., Marsche, G., Frohlich, E., Samberger, C. et al., EP4 receptor stimulation down-regulates human eosinophil function. Cell. Mol. Life. Sci. 2011. in press: doi:10.1007/s00018-011-0642-5.
41. Philipose, S., Konya, V., Sreckovic, I., Marsche, G., Lippe, I. T., Peskar, B. A., Heinemann, A. et al., The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler. Thromb. Vasc. Biol. 2010. 30: 2416-2423.
42. Ulcar, R., Peskar, B. A., Schuligoi, R., Heinemann, A., Kessler, H. H., Santner, B. I. and Amann, R., Cyclooxygenase inhibition in human monocytes increases endotoxin-induced TNF alpha without affecting cyclooxygenase-2 expression. Eur. J. Pharmacol. 2004. 501: 9-17.
43. Takahashi, H. K., Iwagaki, H., Mori, S., Yoshino, T., Tanaka, N. and Nishibori, M., Prostaglandins E1 and E2 inhibit lipopolysaccharide-induced interleukin-18 production in monocytes. Eur. J. Pharmacol. 2005. 517: 252-256.
44. Minami, M., Shimizu, K., Okamoto, Y., Folco, E., Ilasaca, M. L., Feinberg, M. W., Aikawa, M. et al., Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J. Biol. Chem. 2008. 283: 9692-9703.
45. Hattori, R., Shimizu, S., Majima, Y. and Shimizu, T., EP4 agonist inhibits lipopolysaccharide-induced mucus secretion in airway epithelial cells. Ann. Otol. Rhinol. Laryngol. 2008. 117: 51-58.
46. Gauvreau, G. M., Watson, R. M. and O'Byrne, P. M., Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care. Med. 1999. 159: 31-36.
47. Billot, X., Chateauneuf, A., Chauret, N., Denis, D., Greig, G., Mathieu, M. C., Metters, K. M. et al., Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg. Med. Chem. Lett. 2003. 13: 1129-1132.
48. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K. et al., The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 2002. 109: 883-893.
49. Sturm, G. J., Schuligoi, R., Sturm, E. M., Royer, J. F., Lang-Loidolt, D., Stammberger, H., Amann, R. et al., 5-Oxo-6, 8, 11, 14-eicosatetraenoic acid is a potent chemoattractant for human basophils. J. Allergy Clin. Immunol. 2005. 116: 1014-1019.
50. Schuligoi, R., Schmidt, R., Geisslinger, G., Kollroser, M., Peskar, B. A. and Heinemann, A., PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem. Pharmacol. 2007. 74: 107-117.
51. Heinemann, A., Ofner, M., Amann, R. and Peskar, B. A., A novel assay to measure the calcium flux in human basophils: effects of chemokines and nerve growth factor. Pharmacology 2003. 67: 49-54.
52. Hartnell, A., Heinemann, A., Conroy, D. M., Wait, R., Sturm, G. J., Caversaccio, M., Jose, P. J. et al., Identification of selective basophil chemoattractants in human nasal polyps as insulin-like growth factor-1 and insulin-like growth factor-2. J. Immunol. 2004. 173: 6448-6457.
53. Schratl, P., Sturm, E. M., Royer, J. F., Sturm, G. J., Lippe, I. T., Peskar, B. A. and Heinemann, A., Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase. Eur. J. Immunol. 2006. 36: 2401-2409.
54. Sedgwick, J. B., Menon, I., Gern, J. E. and Busse, W. W., Effects of inflammatory cytokines on the permeability of human lung microvascular endothelial cell monolayers and differential eosinophil transmigration. J. Allergy Clin. Immunol. 2002. 110: 752-756.
55. Konya, V., Sturm, E. M., Schratl, P., Beubler, E., Marsche, G., Schuligoi, R., Lippe, I. T. et al., Endothelium-derived prostaglandin I(2) controls the migration of eosinophils. J. Allergy Clin. Immunol. 2010. 125: 1105-1113.
56. Stubbs, V. E., Schratl, P., Hartnell, A., Williams, T. J., Peskar, B. A., Heinemann, A. and Sabroe, I., Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J. Biol. Chem. 2002. 277: 26012-26020.
57. Johansson, M. W., Lye, M. H., Barthel, S. R., Duffy, A. K., Annis, D. S. and Mosher, D. F., Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am. J. Respir. Cell. Mol. Biol. 2004. 31: 413-422.
58. Kamata, T., Tieu, K. K., Tarui, T., Puzon-McLaughlin, W., Hogg, N. and Takada, Y., The role of the CPNKEKEC sequence in the beta(2) subunit I domain in regulation of integrin alpha(L)beta(2) (LFA-1). J. Immunol. 2002. 168: 2296-2301.
59. Heinemann, A., Sturm, G. J., Ofner, M., Sturm, E. M., Weller, C., Peskar, B. A. and Hartnell, A., Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils. J. Allergy Clin. Immunol. 2005. 116: 820-826.
60. Grill, M., Heinemann, A., Hoefler, G., Peskar, B. A. and Schuligoi, R., Effect of endotoxin treatment on the expression and localization of spinal cyclooxygenase, prostaglandin synthases, and PGD2 receptors. J. Neurochem. 2008. 104: 1345-1357.
61. Choi, E. Y., Chavakis, E., Czabanka, M. A., Langer, H. F., Fraemohs, L., Economopoulou, M., Kundu, R. K. et al., Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 2008. 322: 1101-1104.
62. Yamamoto, H., Nagata, M. and Sakamoto, Y., CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1. Ann. Allergy Asthma Immunol. 2005. 94: 292-300.